SeaStar Medical Holding Corp

SeaStar Medical Holding Corp (Nasdaq: LMAO) is the surviving public entity following the de-SPAC merger between LMF Acquisition Opportunities, Inc. and SeaStar Medical, Inc., which closed in October 2022. The blank-check vehicle, sponsored by LMF Sponsor LLC, completed its IPO in 2021 and targeted the healthcare and medical technology sector. SeaStar Medical develops the Selective Cytopheretic Device, a blood-purification technology designed to reduce inflammation in critically ill patients suffering from acute kidney injury and multi-organ dysfunction. The company filed the referenced 8-K current report with the SEC on September 8, 2023, as part of its ongoing disclosure obligations as a post-combination reporting company. Sign up at SpacDesk for full filing history, deal terms, and real-time data on LMAO and hundreds of other SPAC transactions.